BR9507672A - Derivados tricíclicos de dicarbonila - Google Patents

Derivados tricíclicos de dicarbonila

Info

Publication number
BR9507672A
BR9507672A BR9507672A BR9507672A BR9507672A BR 9507672 A BR9507672 A BR 9507672A BR 9507672 A BR9507672 A BR 9507672A BR 9507672 A BR9507672 A BR 9507672A BR 9507672 A BR9507672 A BR 9507672A
Authority
BR
Brazil
Prior art keywords
lower alkyl
pct
disease
amino
signify
Prior art date
Application number
BR9507672A
Other languages
English (en)
Inventor
Bernd Buettelmann
Thierry Godel
Laurence Gross
Marie-Paule Heitz Neidhart
Claus Riemer
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9507672A publication Critical patent/BR9507672A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9507672A 1994-05-24 1995-05-16 Derivados tricíclicos de dicarbonila BR9507672A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH160294 1994-05-24
CH47795 1995-02-17
PCT/EP1995/001856 WO1995032205A1 (en) 1994-05-24 1995-05-16 Tricyclic dicarbonyl derivatives

Publications (1)

Publication Number Publication Date
BR9507672A true BR9507672A (pt) 1997-08-19

Family

ID=25684688

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507672A BR9507672A (pt) 1994-05-24 1995-05-16 Derivados tricíclicos de dicarbonila

Country Status (16)

Country Link
US (1) US5688803A (pt)
EP (1) EP0760819B1 (pt)
JP (1) JP2828506B2 (pt)
CN (1) CN1044245C (pt)
AT (1) ATE194841T1 (pt)
AU (1) AU688515B2 (pt)
BR (1) BR9507672A (pt)
CA (1) CA2189776A1 (pt)
DE (1) DE69518075T2 (pt)
DK (1) DK0760819T3 (pt)
ES (1) ES2149989T3 (pt)
GR (1) GR3034625T3 (pt)
NZ (1) NZ287413A (pt)
PT (1) PT760819E (pt)
RU (1) RU2145606C1 (pt)
WO (1) WO1995032205A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243049A (en) * 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
US5955465A (en) * 1996-03-22 1999-09-21 Neurogen Corporation 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
GB2316616A (en) * 1996-09-02 1998-03-04 Lilly Industries Ltd Modulation of GluR5 receptors in the hippocampus to treat psychiatric disorders
FR2773153A1 (fr) * 1997-12-29 1999-07-02 Rhone Poulenc Agrochimie Nouveaux composes fongicides
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
AU2220801A (en) * 1999-12-22 2001-07-03 Kyorin Pharmaceutical Co. Ltd. Tricyclic compounds and addition salts thereof
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
GB0223730D0 (en) * 2002-10-11 2002-11-20 Novartis Ag Organic compounds
JPWO2005080392A1 (ja) 2004-02-19 2007-08-02 武田薬品工業株式会社 ピラゾロキノロン誘導体およびその用途
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
US7907679B2 (en) * 2007-01-12 2011-03-15 General Dynamics C4 Systems, Inc. Methods and systems for acquiring signals using coherent match filtering
US8139680B2 (en) 2007-01-12 2012-03-20 General Dynamics C4 Systems, Inc. Signal acquisition methods and apparatus in wireless communication systems
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors
EP2166853B1 (en) * 2007-06-08 2014-05-28 Dart Neuroscience (Cayman) Ltd Therapeutic pyrazolonaphthyridine derivatives
WO2009123537A1 (en) * 2008-04-04 2009-10-08 Forskarpatent I Syd Ab GABAa RECEPTOR MODULATORS
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US9156836B2 (en) 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
MX2011004295A (es) 2008-11-14 2011-05-23 Hoffmann La Roche Derivados de quinazolina como antagonistas del receptor de neurocinina 3 (nk3).
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2861071B1 (en) * 2012-04-04 2017-03-15 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
RU2620252C2 (ru) 2012-12-04 2017-05-24 Вольво Трак Корпорейшн Способ и система управления впрыском топлива
CN103073547A (zh) * 2013-02-06 2013-05-01 上海药明康德新药开发有限公司 一种(3aS,9bR)-叔丁基-3,3a,4,5-四氢吡咯[3,4-c]喹啉-2(9bH)酯的合成方法
KR101997955B1 (ko) 2013-04-05 2019-07-08 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체의 염, 및 이의 결정
SG11201507733YA (en) 2013-04-05 2015-10-29 Eisai R&D Man Co Ltd Pyridinylpyrazoloquinoline compound
CN104447736B (zh) * 2014-10-14 2016-06-08 雅安职业技术学院 一种veranamine的合成方法
IL270357B2 (en) 2017-06-01 2024-02-01 Eisai R&D Man Co Ltd A therapeutic agent in Lewy body disease containing pyrazoloquinoline compounds
US11833146B2 (en) 2017-06-01 2023-12-05 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
MX2019013198A (es) 2017-06-01 2020-01-20 Eisai R&D Man Co Ltd Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
BR112019023595A2 (pt) 2017-06-01 2020-05-26 Eisai R&D Management Co., Ltd. Agente terapêutico da demência combinando derivados de pirazoloquinolina e memantina
WO2024012554A1 (zh) * 2022-07-14 2024-01-18 上海日馨医药科技股份有限公司 Tpk激动剂及使用其治疗神经退行性疾病的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
EP0459561B1 (en) * 1990-05-31 1995-09-20 MERCK SHARP & DOHME LTD. Dioxo-tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
CN1044245C (zh) 1999-07-21
EP0760819A1 (en) 1997-03-12
DE69518075T2 (de) 2001-03-22
CA2189776A1 (en) 1995-11-30
ES2149989T3 (es) 2000-11-16
PT760819E (pt) 2000-11-30
EP0760819B1 (en) 2000-07-19
AU2613095A (en) 1995-12-18
CN1149295A (zh) 1997-05-07
AU688515B2 (en) 1998-03-12
NZ287413A (en) 1998-02-26
GR3034625T3 (en) 2001-01-31
DK0760819T3 (da) 2000-10-09
JPH09506634A (ja) 1997-06-30
RU2145606C1 (ru) 2000-02-20
ATE194841T1 (de) 2000-08-15
DE69518075D1 (de) 2000-08-24
US5688803A (en) 1997-11-18
WO1995032205A1 (en) 1995-11-30
JP2828506B2 (ja) 1998-11-25

Similar Documents

Publication Publication Date Title
BR9507672A (pt) Derivados tricíclicos de dicarbonila
CA2783727A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
CN102066384B (zh) 作为α-7烟碱乙酰胆碱受体配体的奎宁环化合物
KR20180095625A (ko) 신규한 화합물
CN108602818B (zh) 吡唑稠环类衍生物、其制备方法及其在治疗癌症，炎症和免疫性疾病上的应用
YU27902A (sh) Derivati benzodiazepina
AU695045B2 (en) Heteroaromatic oxazole compounds and use thereof
WO2001021160B1 (en) Carboxymide and aniline derivatives as selective inhibitors of pathogens
CA2288789A1 (en) Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
DE69222096T2 (de) Tetrahydropyrrolo[1,2-a]Pyrazin-4-Spiro-3'-Pyrrolidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
ATE370735T1 (de) Phenylpyridazinderivate und diese enthaltende arzneimittel
CA2601098A1 (en) Dipyrazoles as central nervous system agents
CA2036163C (en) Novel beta-lactam compounds and their production
DE69415341D1 (de) Kondensierte tricyclische heteroaromatische derivate als liganden des dopamin-rezeptor-subtyps
TR199900946T2 (xx) 2-Metoksifenilpiperazin t�revleri.
JO2307B1 (en) Papermidine derivatives
BR0213177A (pt) Derivados de 5-metóxi-8-aril-[1,2,4]triazolo[1,5-a]piridina
JPWO2002042312A1 (ja) 新規カルバペネム誘導体
WO2001007023A3 (en) Azetidine compounds in cns and eye diseases
IE67525B1 (en) Derivatives of Penem
ES2112470T3 (es) Derivados de piridazinona, procedimientos de produccion y utilizacion.
WO2001007022A3 (en) Azetidine compounds in cns and eye diseases

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 13A,14A,15A E 16A ANUIDADES

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 13A, 14A, 15A E 16A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2607 DE 22-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.